Search
Immuneering Corp
IMRXAdd to Watchlist
4.130USD
-0.100-2.36%
Close 07-31 16:00（ET）Quotes delayed by 15 min
267.20MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Immuneering Corp is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 30.00 and a low of 11.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
18.167
Target Price
+339.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Immuneering Corp
IMRX
7
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Immuneering Corp's price target?
Analysts forecast that Immuneering Corp's price target is USD 14.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 11.00.
How have Immuneering CorpIMRX's recent earnings per share performed?
The market expectation was USD -0.21, while Immuneering CorpIMRX's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for Immuneering Corp?
Based on the ratings of Immuneering Corp's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.